Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
June 25, 2019
Assignees:
Boehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
Inventors:
Kai Gerlach, Christian Eickmeier, Achim Sauer, Stefan Just, Bertrand L. Chenard
Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
Abstract: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.
Type:
Grant
Filed:
August 27, 2015
Date of Patent:
February 20, 2018
Assignee:
Hydra Biosciences, Inc.
Inventors:
Jayhong A. Chong, Christopher Fanger, Magdalene M. Moran, Elisha Singer, Timothy Strassmaier, Howard Ng
Abstract: This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
Type:
Grant
Filed:
August 10, 2015
Date of Patent:
August 29, 2017
Assignee:
Hydra Biosciences, Inc.
Inventors:
Bertrand L. Chenard, Randall J. Gallaschun
Abstract: The invention provides novel compositions and compounds that inhibit CatSper channel activity, that preferentially inhibits sperm hyperactivity over sperm motility, or both. The compounds of the invention are useful as contraceptive agents that may be adminstered to males, females, or concurrently to both sexual partners. The invention further provides methods of conducting drug discovery business and of conducting a reproductive medicine business. The invention also provides methods of identifying compounds that modulate sperm hypermotility.
Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
Type:
Grant
Filed:
March 4, 2011
Date of Patent:
November 8, 2016
Assignee:
HYDRA BIOSCIENCES, INC.
Inventors:
Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, Magdalene M. Moran, Howard Ng, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
Abstract: This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula I and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. A, R1, R2, R3 and R4 have meanings given in the description.
Type:
Grant
Filed:
August 10, 2015
Date of Patent:
September 20, 2016
Assignee:
Hydra Biosciences, Inc.
Inventors:
Bertrand L. Chenard, Randall J. Gallaschun
Abstract: This invention relates to novel Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
Type:
Grant
Filed:
August 10, 2015
Date of Patent:
September 13, 2016
Assignee:
Hydra Biosciences, Inc.
Inventors:
Bertrand L. Chenard, Randall J. Gallaschun
Abstract: This invention relates to novel Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
Type:
Grant
Filed:
August 10, 2015
Date of Patent:
September 13, 2016
Assignee:
Hydra Biosciences, Inc.
Inventors:
Bertrand L. Chenard, Randall J. Gallaschun
Abstract: This invention relates to novel Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 R4 and R5 have meanings given in the description.
Type:
Grant
Filed:
August 10, 2015
Date of Patent:
September 13, 2016
Assignee:
Hydra Biosciences, Inc.
Inventors:
Bertrand L. Chenard, Randall J. Gallaschun